Close menu

July 14th, 2021 | 10:54 CEST

Cardiol Therapeutics, CureVac, Bayer - Where is the journey heading?

  • Pharma
Photo credits:

One might think that the pharmaceutical industry is the big winner of the Corona Crisis. However, according to a study by EY, this is not the case. Sales did increase by an average of 4.4% at the largest pharma companies, a much better result than in many other industries, but compared to 2019, growth actually fell by 8.4%. That is due to the postponement of medical treatments due to the Corona Crisis. The industry benefits from the ever-increasing number of elderly people worldwide and, at the same time, the development of new drugs. As a result, sales and profits have increased even during the crisis. We, therefore, highlight three companies from the pharma sector.

time to read: 4 minutes | Author: Armin Schulz
ISIN: CARDIOL THERAPEUTICS | CA14161Y2006 , CUREVAC N.V. O.N. | NL0015436031 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:

    Cardiol Therapeutics - Waiting for results

    Cardiol Therapeutics is a pharmaceutical company that specializes in cannabidiol as an anti-inflammatory drug for heart conditions. A Phase II/III clinical trial of their lead product CardiolRx, THC free, has been approved by the FDA (Food and Drug Administration) and targets Covid-19 patients. It is now known that COVID is a vascular disease, which explains the increased risk of cardiovascular complications.

    In addition to its use in Corona patients, the drug may also help against myocarditis. Myocarditis may occur after Corona vaccinations. Separately, myocarditis is the leading cause of cardiac death in people under 35, and the drug CardiolRx is designed to counteract this. An international Phase II study regarding acute myocarditis is being planned. The third area of application is chronic heart failure, which affects around 26 million people worldwide. More than 6 million adults suffer from it in North America alone, resulting in over USD 30 billion annual costs in the USA.

    Following a capital increase, the Company is well-capitalized for the time being. There are several research collaborations with institutions in Houston, Alberta and Monterrey. On June 29, the Annual General Meeting was held, and all management proposals received broad support from shareholders. On July 7, the Company announced the retirement of Dr. Eldon Smith. At the same time, Dr. Torre-Amione was appointed to the Board of Directors, having worked for the Company since 2018. The stock is currently priced below the CAD 3.60 issue price of the capital raise. If the studies confirm Phase I results, a jump in the share price is possible here.

    CureVac - Managers sell large shares

    CureVac had been given a lot of advance praise in the race for a vaccine against Covid-19. The German government became indirectly involved via KfW Bank with EUR 300 million and thus holds 16% in the German Company. As it has since emerged, not only was the race for first place lost, but the drug also performs significantly worse than competing vaccines. After this news was announced in June, the stock plummeted by more than 50%.

    CEO Haas still wants to achieve EU approval. In the 18 to 60 age group, efficacy has been significantly better, he said. The Company is also focusing on second-generation vaccines specifically aimed at providing better protection against viral variants. CureVac has brought well-known partners to its side for production, such as Bayer, GlaxoSmithKline and Novartis. If there is no approval, the first batch of the vaccine will probably have to be destroyed. Even the (former) managers no longer seem to have any absolute confidence in their product. On July 12, it became known that four managers had sold off large parts of their share packages.

    The share recovered from its low of EUR 39.10 to EUR 64.51 by the end of June. Since then, the share has fallen back to around EUR 48, possibly following management's share sales. Things look bleak for the stock, which still has a market capitalization of over EUR 9 billion. From this perspective, there is still plenty of room to the downside. At present, it is better to refrain from investing.

    Bayer - Share at a crossroads

    Bayer continues to suffer from the Monsanto takeover and the associated claims for damages in the US. Since the takeover, the Company has been on a downward trend. However, the Company is not doing badly operationally. The pharmaceuticals sector, in particular, is constantly bringing good news. Last Friday, the Group received approval for its drug Kerendia, which treats chronic kidney disease and type 2 diabetes. There are more than 160 million patients worldwide, and analysts see blockbuster potential for the drug.

    In Japan, there were approvals for Vericiguat and Verquvo in June. The Group has been making acquisitions in the pharma space lately, such as Bluerock and AskBio, acquired for USD 4 billion. Thus, a cell therapy company and a gene therapy company are ready to develop further blockbuster candidates. It remains to be seen whether all this good news will help the share price. Since June 22, Bayer has been facing a new glyphosate lawsuit.

    The stock is struggling at the 200 moving average and has dropped another EUR 4 since the lawsuit. Currently, the share costs EUR 50.60. It is enormously important that the share is quoted above EUR 49.69 on a closing price basis in the short term. Otherwise, the next price target would be EUR 46. A decent dividend yield of around 3.9% speaks in favor of the share. Once the Monsanto issue is over, one has to strike at the share.

    Things can go up quickly in the pharmaceutical sector, but they can also go down. Cardiol Therapeutics has the potential to multiply if the drug is approved. CureVac currently has no more potential; investors should instead think about selling. Bayer can probably be bought in the long term because the legal disputes will end at some point, likely leaving the share with significantly more potential.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.


    Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST

    Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!

    • Biotechnology
    • Pharma
    • vaccine

    Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.


    Commented by André Will-Laudien on May 16th, 2023 | 09:45 CEST

    BioNTech, Bayer, BioNxt, Formycon - The next biotech wave is rolling in - select carefully now!

    • Biotechnology
    • Pharma

    Even after Corona, the biotech sector remains an interesting investment sector because it is still important to keep an eye on the major widespread diseases. For many companies, this will probably mean a longer waiting game for investors. In addition to the promising research approaches and milestone plans, the cash reserves of these companies are also important. While having ample funding can lead to quick progress in the laboratory, it is crucial to have the necessary liquidity. In refinancing, however, things have become a little frostier since the rise in interest rates. Which companies should be put under the microscope?